Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...

Unveiling a global crisis: groundbreaking research highlights the immense impact of HSV infections on health, urging a shift towards vaccine innovation and prevention measures. Study: Estimated global ...

The researchers found 25.6 million people aged 15 to 49 years had new HSV-2 infections and 519.5 million (13.3%) had existing (prevalent) HSV-2 infections globally in 2020. (HealthDay News) — The ...

The rise of sexually transmitted infections (STIs) continues to pose threats. The prevalence of one uncurable STI in particular – genital herpes simplex virus (HSV) type 1 and 2 – is at a global high, ...

Herpes is common – and manageable. Here's how it can affect pregnancy, birth, and your baby, plus what you can do to protect them.

Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...

Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage ...

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...